Q2 2023 Twist Bioscience Corp Earnings Call
Yeah.
Good morning, ladies and gentlemen, and welcome to twist Bioscience fiscal 2023 second quarter financial results Conference call.
Later, we will conduct a question and answer session. Just a question during the session you will need to Crestar. One one on your touch on telephone you will Daniela automatic message advising yohan its ways I would now like to turn the conference call over to Angela bidding senior Vice President of corporate a fast and cheap ESG officer. Please go ahead.
Thank you operator, good morning, everyone I'd like to thank all of you for joining us today for twist Biosciences Conference call to review, our fiscal 2023 second quarter financial results and business progress.
We issued our financial results released this morning, which is available at our website at Www Dot twist Bioscience dotcom.
With me on today's call her Doctor, Italy, La Cruz, <unk>, CEO and co founder of twist, and Jim Thorburn CFO of twist.
And we will begin with a review of our recent progress with businesses, Jim will report on our financial and operational performance, then Emily I'll come back to discuss our upcoming milestones and direction we.
We will then open the call for questions. We would ask that you limit your questions to a maximum of two and then requeue as a courtesy to others on the call.
As a reminder, this call is being recorded the audio portion will be archived in the investor section of our website and will be available for two weeks.
During today's presentation, we will make forward looking statements within the meaning of the U S Federal Securities laws.
Forward looking statements generally relate to future events or future financial or operating performance.
Expectations and beliefs regarding these matters may not materialize and actual results in financial periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
These risks include those set forth in our press release issued earlier today as.
As well as those more fully described in our filings with the Securities and Exchange Commission.
The forward looking statements in this presentation are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward looking statements, except as required by law.
We will also discuss financial measures that do not conform with generally accepted accounting principles, including adjusted EBITDA.
Information may be calculated differently than similar non-GAAP data presented by other companies when reported a reconciliation between these GAAP and non-GAAP financial measures will be included in our earnings documents, which can be found on our investor relations website at www Dot twist Bioscience Dot com.
With that I'll now turn the call over to our Chief Executive Officer, and co founder Dr. Emily Ellipsis.
Thank you Angela and good morning, everyone isn't a busy time for twist and very pleased with our performance for the first half of the fiscal year in Q2, we delivered our first quarter was $60 million in revenue. In addition, this morning, we announced that we have taken strategic actions to accelerate the stability I am happy to.
We expect to achieve a quarterly run rate adjusted EBITDA breakeven for both the coal and Biopharma businesses.
September of 'twenty 'twenty four quarter.
16 months.
Today I will focus on three main themes.
Our confidence in our near term revenue growth second our decisive actions designed to achieve adjusted EBITDA breakeven in the near term and filled the drivers of growth in all businesses moving forward.
Beginning with top line growth of our revenue generating businesses and I'm pleased to share a very strong result for the second quarter of fiscal <unk> suite with reported record revenue of $60 2 million exceeding our guidance of $56 5 million at all.
Strength in the core business, Australia, NTS growth, although came in at $64 2 million alone, indicating solid growth moving into the second half of our fiscal year.
During the quarter, we began commercial shipments at Wilsonville, Oregon facility the effects of all the future, which we believe will deliver manufacturing efficiencies leading to margin improvement going forward. We continue to see increasing it to give them called genes, Jim Cramer oligo pool elaborate products, we've got consistent rapid.
Time dropping.
I'd like to note that this is for al Stubhub speeches, we have not yet taking order for fast genes, which we expect to launch in the fall with premium pricing.
We continue to take market share from appeal and remain fall ahead of emerging players because of our consistent on time together with a perfectly to genes at the scale and price.
Elsewhere, which.
Which continues to resonate with our customers.
A reliable products and exceptional customer service is the key to creating loyalty with our guests know, which then facilitates reorder quarter over quarter revenue growth in.
In addition, our guests know surveys.
Please state that we are the preferred provider because other than it's easy and we all know deliver on canola.
Funds, yes, we see shifts not advancing development of their pets, and they're still gaining traction within the market.
Yes revenues significantly linked to the commercial ramp of our customer base and while there can be quarter to quarter Lumpiness, we have confidence that revenue will grow year over year.
The point to remember is our.
Our business is sticky we grow without just the mill and our customer base continues to expand.
And by the summer we began integrating the Boston team at the end of the calendar year Halloween the contractual limitations of the acquisition.
We continue to see opportunities ahead, particularly as we now have an integrated team and portfolio of services.
It is true that the funding environment for emerging biotech companies has been constrained.
The bus from it services market is small.
Largely untapped by our commercial team.
Ed we are facing some internal headwinds as we reap that phone system and integrate commercial territories.
We've made changes to address these challenges and expect the revenue lift will come within six months.
We continue to sign collaborations and agreements with customers and we're expanding our wallet share with existing partners.
An example, why not then those arguments with Astellas in April 3rd collaboration with these pharmaceutical company, we do expect fewer months in the royalties for corporations as we move along as we are now prioritizing near term top line revenue growth.
Our commercial team for <unk> and GSM pharma is now firing on all cylinders and we are seeing a lot of opportunities ahead.
I will now move from top line to operating expenses and our significant actions to accelerate our path to profitability.
As you know the frac of the future outside of Portland, Oregon is now shipping products with customers.
All of our <unk> framework.
Vast majority of politico.
Politico pools have been made in Oregon for more than a month.
To accelerate our top line to reach profitability, we conducted a comprehensive review to reengineer, our cost base and achieve these goals more quickly we've made difficult decisions. We sizing may teams throughout the organization, which will result in the elimination of approximately 270 positions to operate.
Additionally, while still continuing to support our high growth areas.
It is difficult to say goodbye to the many talented and committed twisters, we've been integral in our success to date, we wish them well, we will support them.
Interface that makes the opportunity and we look forward to what they would achieve as they bring that expands from twist to the larger ecosystem.
To provide a bit more color on the shape of the organization moving forward. The Salesforce, we remain largely intact to drive top line growth, we remove duplication of C&I production across silicone lenses bachman significantly lowering our fixed cost structure. In addition, we will size the biopharm.
Our team's focus on revenue generating partnerships de prioritizing the majority of our internal assets throughout their organization with streamline teams and training R&D to focus on programs, where Twitter is a clear competitive advantage and to selectively deploy our platform in areas, where we see the greatest potential for long term.
The accretion.
Yeah.
In data storage, we remain integrally involved in market development and continue to advance our technology.
We do not see a near term competitor of cliffs commercial launch at this time and that's significant.
It enables us to substantially reduce our operating expenses for the storage, while continuing our effort at the moment that sliver.
We made ahead of the competition, we will focus our efforts on the storage as a service business model and plan to delay the distributed oncoming approach until after the service business has proven to be a success.
We expect to demonstrate an end to end gigabytes century archive service by the end of calendar 2023.
On this in early calendar 2025, we expect to launch a terabyte centrally archive solution.
We believe we will deliver on all of this while reducing the overall cash bill.
Looking into our future growth, we see many opportunities ahead as.
As we look for the planned launch of fast Jason before we will be targeting the $1 4 billion and.
Makeup market. These are scientists and researchers and large pharmaceutical companies that currently made their own G&A instead of buying it as they need it faster and more cost effectively and we believe it can be delivered from virtually any source today.
This is one area that we are confident we will increase our sinbo contribution margin as we believe we'll be able to command a premium price that leverages dynamic pricing for our rapidly delivering these products.
Additionally, we do not expect to add commercial head count two posted this last March market as with many of our E Commerce portal and digital marketing capabilities enabled us to acquire the mill cost effectively.
20th our customers continues to increase particularly in the oncology space. We have several large commercial just to note on a growing media group of development stage, just the mill with the potential for compounding book in both instances twist is poised to grow with them.
We continue to be included in more and more assets and we believe the growth of our <unk> opportunity will be sustainable for the foreseeable future.
We plan to an RNA workflow tools to our NCS portfolio scientists <unk> RNA assays multiple times for the Samsung <unk>.
As R&D tenancies at different time points and different issues in both normal and this is states, providing a large market opportunity that confluence of workflow tools.
Workflows.
Similarly, within the research market and area, where we haven't seen sequentially smaller footprint to date, but believe we can grow and expand.
We expected on several R&D tools in the near future.
And by pharma, we continue to see opportunities for our competitively priced high value services.
And also with the integration of the offerings.
We focus on selling services that drive top line revenue, while we digest the recycling of the organization the largest shift will be aware from R&D.
Our internal assets until we see some of them you mean, the out licensing of <unk>, where we have done the most work.
For the storage the very large opportunity remains within our sites because one notes in direct competitors at this time.
Slowing investment therefore, we have revised our commercial plans, while we advance at the more modest rate with us using our first will be our best in class.
Advantage.
With that ill turn it over to Jim.
Alright, Thanks, Emily we had another quarter of robust execution at twist, despite a volatile macroeconomic environment.
Revenue for quarter, two was $60 2 million, which is year over year growth of approximately 25% and a sequential increase of 11%.
Margins were $64 2 million for the quarter, an increase of approximately 17% year over year and gross margin for the quarters Thats, 8%, we shipped approximately 2100 customers as compared to 2000 and quarter two fiscal 'twenty, two and we ended quarter, two with cash and investments of approximately $388 million.
Our Ngls revenue for quarter, two was $29 million, which is year over year growth of 26%.
As we noted in our previous earnings call. We had a couple of larger customers pushed shipments from the December quarter into January our second quarter orders were $28 million, a sequential decline of 10%, but growth of 19% year over year as Emily stated revenue growth in Ngls is linked to the ramp.
Of our customer tests, which can drive some cautious quarter lumpiness in revenues.
10 customers account for approximately approximately 38% of <unk> revenue and we served approximately 600 mgs customers' fiscal quarter to our pipeline for larger opportunities continues to scale and we're now tracking 270 <unk> up from 264 notes in our last earnings call.
<unk> 31, a adopted twist as compared to 170 last quarter.
Now turning to send vital which includes genes DNA, perhaps agg libraries, and the oligo pools sent by our revenue for the quarter rose to $24 1 million representing a.
A sequential growth of 11% and year over year increase of approximately 31%.
Orders for the quarter with Tak, <unk> 9 million, which represents a 16% sequential increase.
31% year over year growth.
Some of the highlights include shipping to approximately 660, <unk> customers, which has grown from approximately 4500 in the second quarter fiscal 'twenty two.
The customer base includes many biotech and large pharma companies.
<unk> revenue increased to $18 million, which is year over year growth of approximately 27%.
We shipped approximately 152000 genes in fiscal quarter, two which is an increase of approximately 23% year over year.
And I'll, let go pools had another strong quarter with revenue of $3 3 million with demand primarily coming from the health care segment.
Now to Biopharma Biopharma revenue for the second quarter of fiscal 'twenty, three was $7 million down sequentially from $8 2 million or just for the quarter of $5 3 million down sequentially from $6 9 million in the first quarter, primarily due to integration challenges Emily described.
That said, we had 93 active programs at the end of the quarter and added three more milestone and royalty agreements, which brings the total to 66 up sequentially from 63.
I'll now cover our revenue breakdown by industry and our regional progress health care revenue for the second quarter of fiscal 2003 was $33 8 million as.
As compared to $24 1 million in the same period of fiscal 'twenty two industrial chemical revenue was $14 4 million in the second quarter of fiscal 'twenty, three as compared to $14 1 million in the second quarter of fiscal 'twenty two.
<unk> revenue was $11 1 million in the second quarter of fiscal 'twenty, three as compared to $9 5 million in the same periods in fiscal 'twenty two.
EMEA revenue rose to $18 8 million in Q2 fiscal 'twenty three versus $15 2 million in Q2 fiscal 'twenty to APAC.
APAC continued to see recovery in China, but our revenue in China, increasing to approximately $2 million up for $1 4 million in the prior quarter for APAC overall revenue increased $6 5 million compared to $4 5 million for the same period of 2002.
U S, which includes Americas revenue increased $34 9 million in the second quarter versus $28 5 million the same period.
<unk>.
Now moving down the P&L.
Our gross margin for quarter, two was 38% with cost of revenue for the quarter of 41 7 million change in gross margin was expected as the cost of revenue increased sequentially from $29 4 million, primarily due to approximately $5 million associated with the commercialization of the <unk> biologic patch in future. In addition, we had approximately $1 million.
Scrap associated with the factory of the future in the quarter.
Our operating expenses for fiscal quarter, including R&D SG&A change in fair value and Mark to market adjustments of acquisitions is approximately $8 1 million as compared to $79 2 million in Q2 fiscal 'twenty two to break it down R&D for this fiscal second quarter was $27 4 million of Dick's.
For the $51 2 million in the same period of fiscal 'twenty two.
Primarily due to the conclusion of <unk>. This includes DNA storage R&D spend of $5 million and Biopharma R&D spend of $4 7 million in the second quarter of fiscal 2003 SG&A in quarter. Two is approximately $54 million, primarily that future pre commercialization costs included in SG&A were approximately $6 million for the first one.
For the quarter manufacturer, but it's not yet commercial in addition, we have a number of labs that are still on peak commercial fast launch physician to Cogs as Theyre qualified in the second half of fiscal 'twenty three stock based compensation for the quarter was approximately $10 million depreciation and amortization for the quarter was $7 1 million an increase from five eight.
In the previous quarter and associated with the commercialization of factory of the future.
Capex cash investments in the quarter, two was approximately $9 million, which brings total capex cash spend for the first six months of fiscal year 'twenty 1 million.
As we've highlighted the launch of the factually features going very well, we had a strong quarter of operational performance and as noted we continued to see year over year growth in <unk> and NCS businesses, we're focused on achieving adjusted EBITDA breakeven and then profitability as we scale we are resizing the organization.
<unk> by approximately 25% with reductions aimed at managing our operation cost structure low.
During our revenue breakeven point and limiting our investments in data storage as we transition to breakeven.
Note the reductions outside of the U S may be delayed as we work through the required regulatory processes.
About 60% of the staff reductions affect the Cogs line and 40% affect Opex in particular, we have resized the biopharma Biopharma group to achieve breakeven at $40 million instead of revenue of $18 million and for the core business. We have streamlined the organization across the board in order to achieve breakeven the $285 million and status.
$300 million cash restructuring costs are estimated to be approximately $9 million to $11 million, we anticipate cash savings of approximately $9 million to $11 million per quarter on a go forward basis, beginning in the first quarter of fiscal 'twenty for savings.
Savings, primarily impacting our operations as we exit gene manufacturing, so San Francisco and ramp up the factory in future as well as moderate our investment in R&D with the majority of this spend reductions in Biopharma and DNA storage, because we've taken actions to address our cost structure. We do believe it is prudent to revise our revenue for fiscal 'twenty three.
We digest. These changes we are revising our guidance to approximately $275 million to $238 million.
Our prior guidance of $2 $61 million to $69 million sitting by our revenue.
Range is $96 million to $98 million, and that's down from $104 million to $106 million and GFS revenue range of $113 million to $114 million down from 120 to 153 Biopharma revenue is $26 million.
That's down from 10 to 740.
For the second half of fiscal 'twenty, three we anticipate revenue of approximately $60 million to $61 million in quarter, three and 62 to 63 million in quarter, four and gross margin to be approximately 30% in Q3 and 36% in Q4.
For the full fiscal year, we are projecting gross margins of approximately 35% to 36%.
We are decreasing operating expense guidance for the year to approximately $313 million to $319 million as compared to our previous guidance of $330 million. We're now projecting R&D expense of $112 million to $114 million as compared to our previous guidance of $130 million, we expect SG&A to be one.
$197 million to $200 million and Thats, a decrease from our previous guidance of 204 million Mark to market is projected to be a credit of 5 million onetime separation costs from our reduction force are projected to be $9 million to $11 million depreciation and amortization is projected to be approximately $29 million.
Our projection for stock based compensation with the claims of approximately $4 3 million from $50 million.
Operating expense for DNA storage.
To be approximately $40 million compared to the previous guidance of $46 million and for fiscal 'twenty. Four we also expect $40 million operating expense for data storage compared to previous guidance of 57 net operating loss of the year is projected to be approximately $230 million to $234 million, which includes one time charges of approximately.
Great.
$11 million for separation costs.
Capex for the year is projected to be four 2 million a decrease from previous guidance of $50 million ending cash projected $320 million compared to previous guidance of $300 million.
In summary, we had record revenue in quarter two were commensurate commercially shipping from the factory of the future. We're focused on managing the business and our cost structure as we scale importantly, we expect to exit fiscal 'twenty four for the fourth quarter adjusted EBIT breakeven for the core and Biopharma business, we define adjusted.
<unk> EBITA as EBITDA plus add back for stock based compensation.
And we're also projecting ending cash balance of $220 million at September 32.
2024, and that's up from our previous guidance of $170 million.
With that I will now turn the call back to Emily.
Thank you Jim we continue to have aggressive goals and we have aligned the business just <unk> seem to be kind of opportunities.
As importantly, we announced decisive and proactive actions to accelerate our pads stability preserving cash and mitigating risks all while leveraging our outsized opportunities in the marketplace.
We always evaluate the business from evidence and we remain laser focused on achieving adjusted EBITDA breakeven for coal and Biopharma businesses, while maintaining optionality on investments for the incredible upside we see in that is storage.
Copies Estenson buy in Ngls continue to scale and we have near term opportunities for each with an upsized commercial teams deployed we are revising and refocusing the Biopharma organization from an integrated service offering that we believe will drive topline revenue growth and we have moderated our stand for storage.
While ensuring we maintain our competitive edge.
We revised our guidance to a cautious level with potential folks side, we've been strategic action this quarter positioning us as a leaner organization, specifically focus on disruptive market opportunities are profitable and scalable.
With these substantive changes we believe we're operating from position of strength in the current environment.
<unk> are predicting timeline to adjusted EBITDA breakeven for both the <unk> and Biopharma businesses.
We exited the September 2020 full quarter.
All about 16 months from now.
We remain extremely excited about trading in the future and with that let's open the call for questions operator.
Thank you, ladies and gentlemen to ask a question you will need to press star one on your telephone and wait for your name to be announced after.
As a reminder to accommodate all participants in the queue. We ask that you. Please limit yourself to one question and follow up if you have additional question you may re enter the queue John from Mitch, Ladies bonbon will be compelled to Kenny roster.
Now first question coming from the line of.
Vijay Kumar with Evercore ISI. Your line is now open.
Hey, guys. Congrats on the revenue beat in the quarter and thanks for taking my question.
I guess my first question is on the guidance there.
It makes sense for the guidance to be reset given the environment.
Back half year, I think implied is high single digits and it looks like all segments were cut, but perhaps biopharma a little bit more than the others can you just talk about the macro environment.
Is this.
What has changed versus three months ago from a macro perspective.
And.
How much of this is twist <unk> stopped the general environment that Youre seeing and how comfortable are you in this.
High single digit growth for the back half.
Thanks Vijay.
One.
In terms of Biopharma, we feel very good about where we're at the challenges we've had in Biopharma is purely installations. So that's an execution issue.
We acquired embarrass last year and they had been early in <unk>.
Horton that we support are embarrassed soon too.
Yes.
And then as we start to integrate we realized we had some integration challenges.
We are launching the <unk>.
The new offerings.
Good.
<unk>.
Because of the internal challenge there.
Reduce the revenue outlook for Biopharma.
It's a large market, we get great service offerings. So we feel very well positioned in terms of the other two areas.
<unk>, yes.
We've just reduced the organization by approximately 25%.
We believe it's going to take some time to digest that reduction.
The overall order growth rates are solid.
<unk> gross margin customers, we're launching new products at the same time $10, 25% of the organization. We believe we need to be prudent in terms of.
So top line I think the advantages and we're positioning the company to get to adjusted EBITDA breakeven.
Earlier and come out with a stronger balance sheet. So this is this is in general but.
But we really really believe that.
Well positioned platform, we're seeing large customer growth so.
As more.
On the on our part.
Understood and just sorry, Jim on.
Just to clarify that point.
What youre, saying is.
5% head count reduction.
And did that come from the commercial side, because I think what you are saying its orders and customers.
The market seems to be healthy, but this is more.
A function of the restructuring actions, you've taken and hence the guidance Im sure in the back half.
That's correct.
Yes, the markets market is strong.
As we highlighted year over year, and we're growing fast in the market.
Where we're focused on launching new products. So this is just.
Pure internal.
Issue in terms of digesting such a large change.
And we've made.
Got it.
We've done a great job in terms of lunch infection future is going exceptionally well.
We believe.
Next six months, we can be prudent in terms of our outlook.
Two the reduction.
The organization by 25%.
Understood and then one on gross margins, Jim if I look at your third quarter and fourth quarter comp commentary here.
Fourth quarter revenues up a couple of million, but I think the implied gross profit dollars are up $4 million.
What drives that.
The right jump off point for next year, how should we think about gross margins for <unk> 24.
Good question.
As we continue to scale.
Yes, you can imagine.
That 76% and starting off point for next year and as we continue to scale.
See incremental improvements in gross margin.
I mean, our focus is get it to that.
Adjusted EBITDA breakeven for the core business by Q4 next year.
We want to leverage the factory of the future, what's driving the new products fast genes, what's driving the new products and Ngls.
We are very very well positioned to see gross margin improvement next year.
Okay.
Thank you and our next question coming from the line of Matt <unk> with Goldman Sachs. Your line is now open.
Hi, This is <unk> on for Matt are you feeling any weakness from the biotech funding environment and then what is your exposure as a percentage of revenue look like for that.
So so in terms of the biotech funding environment I mean, clearly, it's having an impact on the overall industry I mean, we see it as an opportunity.
Barris on the.
Biopharma integration, we're going to be launching.
Integrated offering.
<unk>.
Sure.
Adjustments in terms of the organization and we're very focused on streamlining the business.
We anticipate getting to adjusted EBIT breakeven of forgings from Biopharma.
The same timelines as usual.
Huge market for us.
So last quarter.
The number of customers dealing with us.
The solid wood.
<unk> see strong strong growth in terms of the number of projects in a number of projects.
Yes.
The offering.
We're feeling good.
So I think.
Overall, and maybe there is issues however.
Our issues have been internal.
And sorry, I missed the second question you asked.
Just what was the percent exposure.
As a percentage of our overall revenue to the biotech.
Environment.
We don't.
<unk>.
This was that overall.
Our healthcare revenues.
50, 50 odd percent.
Our overall business and that's been growing year over year.
So so.
It gets back to the strength of our product offering and.
Yes.
Our customers reduced sequencing sequencing costs fast time from sample to sequencer sym bio our campaign to scale into.
Biotech and with the <unk>.
<unk> pharma business will have an integrated offerings. So we see ourselves moving into large pharma customers.
<unk> to be a good trend for us.
So overall have you looked at our arden's, our orders are up year over year revenue is up year over year.
I mean, we are focused on execution and we believe that due to the <unk>.
Not far.
By significant volumes in your customer base.
Okay, Great. That's helpful. Thank you and then where is the.
Cost reduction mostly weighted towards is it like towards one specific specific segment or is it pretty equal across the board.
Cost reductions are.
Yes.
The board.
We're managing our data storage investments.
We've adjusted the.
On Biopharma cost structure.
For the core business.
We've migrated.
Our gene business to function in the future. So we're leveraging that is actually in future investments they're taking.
Taking advantage of the fast turnaround time.
Segments.
The outcome is for our core business and GFS.
<unk>.
Biopharma.
Bold as to get to adjust you mentioned breakeven by Q4 next next year.
Exit next year.
<unk> cash position.
Great. Thank you.
Thank you and our next question coming from the line of <unk>.
Adler with William Blair. Your line is open.
Hey, good morning.
About data storage. So obviously mentioned you're moderating expenses there, but I know you also mentioned that you've kind of given significant lead just curious why that level of reduction in spend.
With the right one that you'd contemplate perhaps more are pausing or maintaining the investment just sort of.
Given that it's a modest reduction.
Want to get a sense for what was contemplated and wind up steadily.
Sort of that level of investment.
Yes, Thank you Matt.
Great Great question, I think we see a tremendous opportunity in the storage for long term value creation.
At the same time, we still have to deliver short term value.
So we have to make some of the.
So food.
Capital allocation.
Seasons.
We.
I am seeing is.
The market for that is the more we sense it.
The more so than we are about it at the same time as I mentioned.
Head <unk> shoulders ahead of the competition and so we see that.
Investment is it.
A level that we have in managing the business.
So.
And we are focusing on adjusted EBITDA breakeven political on Biopharma business and ending getting there.
Cash in the bank is placebo.
We will too.
Lower investment in the destination without losing our competitive.
Edge. So what that means is we will have to do less so we'd do a bit less of market development.
We're not going to do the early access with the gigabyte chips. Instead, we will show the end to end demonstration, which is important that foods systems, it's going to should we can do that that in that the out but we don't have to go commercial with that system. Instead, we're going to <unk> ongoing commercial with the next.
<unk> terabyte cheaper machine going to be.
Disruptive from a total cost of ownership point of view.
That's a significant change.
The gigabyte chip was most of the demonstration and so we're not going to commercialize something Thats administration extends working at and focus on commercializing.
A chip that is service based on achieved disease.
Disruptive from the one where we can get <unk>.
Revenue growth and really good margin from day one.
Okay understood.
And then if.
If we sort of look at your quarterly resulting.
Bear out that <unk> and yet you entered this market desk disruptors.
Taking share growing above market and its more challenging on the outside looking in to look at Biopharma and assess.
That has been going just given the number of acquisitions that you've made there.
From the outside looking in that market seems to be a bit more crowded and certainly evolving.
What's your assessment of kind of you mentioned sort of the renovated assets, but you're also going through something some internal changes what's your assessment for the.
The offering you have there relative to your assessment of competition and how you think you're growing perhaps either modest measured by win rates or pitches or revenue what sort of the right metrics youre looking at internally that gives you confidence there.
That that asset is really a competitive and differentiated.
And that's a very good question and so from a technology point of view.
Our technology.
Individual technology from the original twist.
We know that that is.
Very strong.
Best in class.
Technology, we have scientific data.
Third the miles that we got from <unk>.
There is no head to head with those amounts.
<unk>.
Best in class as well and so the combination together plus the addition of <unk> we headed.
Our belief is that.
That is the best set of tools comprehensive goal stood down to G can have for antibody discovery.
So from a technology point of view extremely confident.
From a commercial point of view.
We.
It's a different story.
In the 10 that we made the decisive actions, we did or the sales team is untouched basically.
In Biopharma, we had to completely retooled our sales team.
So we're in a situation, where we have fantastic technology that we strongly believe in disruptive into twist spirits were when we're doing we're going with it.
In fact vantage and we've just now we can place.
The commercial team that is going to.
<unk> that technology, so in terms of metric to look at.
What we report to the Street is all those all those have been done.
So what we're going to look for is a reversal of orders.
All of those.
As the first step to getting to revenues and in Biopharma.
All the other of the upfront payment. So usually there is a 100% conversion to revenue. So what we're looking at is <unk>.
And then in terms of from internal metric.
It's a classic sales pieces development.
So the metrics what are the activities.
Pretty.
Now many of you as soon as we get in we have a secret weapon, we though so.
So Aaron settle.
Although <unk> and then we can have the sales team.
Look up.
And then.
Extending the scientific level of our sales team to be able to do more of that.
At this point.
We compete on some of the technology, we have and it's a sales business development execution from now on.
Okay. Thank you.
Thank you and our next question coming from the line of Steven <unk> with Cowen. Your line is now open.
Oh, great. Thanks for the question.
Question for Jim could you give us some color on the Capex pull back in 2023% from $50 million to $40 million and then.
Follow up on that is it going to be any impact on the fact that the future build out and fast gene and RNA launches launches out of the factory of the future because of that.
Yes, thanks for the question Steve.
In terms of the Capex pullback is just.
Physically in managing our Capex.
We see no no impact.
The key thing for us over the next.
Four five months.
To execute in terms of.
Taking into account the impact.
Reduction in head count.
So as part of this we have an ongoing focus in terms of financing.
Our capex managing our networking capital.
Continuing to drive growth.
Same time manage the balance sheet, so just prudent management.
And there'll be no impact in terms of.
The factory in the future.
Okay. Thanks for that color and then a question for Emily.
The enhanced whole genome sequencing and enhance whole exome sequencing early access programs can you give us some color on how the response has been and how the traction has been there and then secondly, I noticed that the partial release on aster insight.
Could you give us a little bit of color on how the economics and revenue share work.
With a partner like Astro insight. Thank you.
Great questions. So on EW EW GFS.
The initial customer feedback has been very positive.
Going too.
Leverage debt.
That technology to the.
Future business.
Well with cost.
Simple is.
Extremely tight.
We see that this way of prices King.
And so.
The technologies that we have.
Developed internally is really.
Moving to enable those <unk> customers.
To do.
Hundreds of thousands millions of samples.
At the very low cost.
Is very high.
<unk>.
On the tumor type to diluted.
And so those are big contract.
When they land is going to be.
Big Big lumps.
It's going to take care of it could be this time.
But the initial technology assessments is extremely positive.
Whats the second question I'm, sorry, yes, yes.
Oh it was.
On the economic share with Aster insight.
On your on your cats, where you're using some of their content on your platform.
Yes.
What we can say is that.
It's built with expertise.
<unk> had some custom nzf's tools.
And.
They are a great channel.
But we're not sharing the economics.
Okay alright, thank you.
Thank you Steve.
Our next question coming from the line of sung <unk> Nam with Deutsche Bank. Your line is open.
Hi, Thanks for taking the questions.
Just to expand on Matt's question earlier with regards to just.
Could provide more color.
Around kind of the rationale in your thought process in terms of the timing and the magnitude of the restructuring.
And what gives you confidence that this.
It might not be overly aggressive or or I guess not.
Not sufficiently enough.
To drive growth in the future just kind of.
Good.
Give us a bit more.
Information there.
Yes.
Okay.
I think normally.
Well, maybe I'll start there.
With a high level and Jim we keep hitting the details so.
The general principle was that.
From a companion morale point of view, we wanted to do it.
And so we don't want to attribute driven so we could really really deep.
We didn't have to do it at the same time, we are assuming that we have.
Some strategic hires that we have to make and so we.
We get deep enough.
To make sure that we left room for those two strategic hires.
That has to happen so.
That was the.
High level.
In principle on the highlight Jim fill in the details.
Yes, so in terms of timing, we launched in factory in future.
Total cost from commercialization.
Scoring going really well.
We've invested significantly over the last.
18 months.
Sure.
In terms of the.
Timing right now we're seeing we're seeing the benefits of our investments.
And we're seeing the opportunities in the marketplace.
A lot of interest in terms of.
Factory in the future.
Hours getting well positioned to launch fast genes and what's important to US also is maintaining a strong balance sheet to support the business as we move from.
Losses to adjusted EBITDA breakeven by Q4 next year, so that gives us the runway for our core business to get there.
At the same time.
See opportunity for top line growth.
Continued opportunities for R&D organization to intervene.
This.
Since restructuring supports the balance sheets for the company and supports our focus on innovation and growth.
Okay got it.
And then in terms of the fast gene could you remind us kind of where the key remaining steps in terms of.
When the market development standpoint, or manufacturing capability standpoint.
The remaining before you.
Before your launch.
Yes. Thank you great question so.
All of the genes as of late March genes in five months and most of the year ago pools are being made in Wilsonville, Oregon.
And so we now are stress tested that.
Factory under a high volume and <unk>.
The performance the turnaround time and.
The final yields equivalent to what we were getting in the <unk> fab.
And the tough time right now.
Is blazing fast averages.
10 days in the 19th percentile of the shipping in 14 days, So it's really great performance and now.
In terms of SaaS team to each.
Two questions.
The two avenues that we're still working on and both on software.
The venue is.
We have internally.
<unk>.
Subsequent to that.
<unk> to enable.
Fast genes. So the process is the same but we are adding most of twin tools such that the days less human intervention less human thinking in terms of what has to happen next.
And that means that the gene.
<unk> will spend less time waiting in the <unk>.
<unk>.
Yeah.
It has to happen next.
The software tools.
The suggestions being fantastic it's on track.
One piece of software.
And that is the extent alone.
The e-commerce tool it needs to be.
Abated, we're adding a key feature of dynamic pricing.
That would be in our view very critical in extracting the most value at the speed that will be created.
Great. Thank you so much.
Thank you and our next question coming from the line of Louis <unk> with Barclays. Your line is open.
Hey, guys.
Good morning.
Couple of things here. So I just wanted to follow up on <unk> question about.
The step up in the margins, there and <unk> with minimal step up in.
In revs.
You provided some early color there, but I thought that the factor of the future.
And the fashion is coming online that was that was all going to be incremental.
Talk about kind of the dynamic there about maybe cannibalizing some of your past work.
The.
Fast change in how the factory of the future is coming online.
Yes.
Yes, just in terms of the.
The step up in margin.
From Corpus Street corner for less driven by top line revenue growth.
As we continue to leverage the actually the future.
In terms of the impact of restructuring.
We see our cost benefits.
Really coming in.
Q1 'twenty four.
And the step up you're seeing there is partial impact of the cost benefits from the leverage factor in future in Q4.
This year, but as you move into Q1, you see the full benefit.
Cost improvements and then you get the impact was as fast genes as we launched in the fall so the fast genes benefits.
As is all fiscal 'twenty four and you see also the full benefit of the cost reductions.
Starting Q1 of 'twenty four.
So in the short term received partial benefits cost.
Cost reductions do you see the benefit of leveraging the fixed cost as we scale revenue sequentially and then as you move into next year.
We will anticipate.
Moving towards adjusted EBITDA breakeven by Q4 of fiscal 'twenty four.
Alright, so I mean does it just follow up on that so if it's.
I guess I get that Youre, recognizing a lot of those cost benefits, but so.
So that on the guide down is it that the fast genes in the factory of the future taking longer to ramp.
Now.
So the guide down.
So two key components. One is the guide down is on the Biopharma business.
<unk> Biopharma business guide down is because we've had internal integration issues.
From a commercial point of view in terms of.
Environment, Yes the.
Only reason, we've taken the guidance down.
We'd see some.
Potential risks of digesting, a 25% reduction in our organization.
Not because of any market issues is because of our own internal prudence in terms of managing such as such as ours.
<unk> transition.
Alright, Great and then last year for for Emily.
On the internal candidates into decision. There you said that youre going to I think you said you're going to stop.
Internal.
Development so.
I thought when you guys had those it was basically in this might be oversimplifying, it but I thought when you had those it was basically the code that you could just store or like keep on ice so.
Talk about the incremental spend that those required.
And then just I guess, the lack of whats driving I guess, the lack of interest among partnerships there for those candidates.
Okay, great Great question so.
Yes, we have been developing some internal candidates.
Those were.
In terms of our R&D investments.
Net.
Swinging away the investment that we've done.
What we are doing is slowing so the investment into those assets.
And so we're focusing now on monetizing those assets and.
As we monetize them as that creates upside.
We will decide then we allocate the capital.
Sure.
Yes.
That could be the tree go too fast.
Further develop.
Assets, but at this point.
It's prudent for us to sell.
The biopharma business such that can be adjusted.
EBITDA breakeven at $40 million revenue instead of $80 million.
So there'll be less R&D on our own assets.
We.
Stoping.
The monetization.
Yes.
<unk> been doing and I wouldn't say that.
There is no interest.
But.
We don't have.
We only limited.
Capabilities.
Outsourcing antibodies, we've done at least.
One we had of out licensing.
Last year.
But we have limited time and resources inside the company to do it until we don't want to get the <unk>.
R&D development ahead of the monetization scheme and so.
What we're doing.
Okay. Thanks.
Thank you and our next question coming from the line of Puneet <unk> with SBB Securities. Your line is now open.
Yes, Hi, Emily and Jim Thanks for taking the question. So first one really is.
Why is this guide cut.
And the last one just given the situation in the macro the biotech funding and the Dx Moderations, which I think everyone. On this call is aware of.
Those things are not necessarily immediately improving in the market.
We have seen guide reductions from a number of companies multiple times. So at this point in time.
Workforce reductions are also opening diagnostic companies and Theyre cutting expense. So your reduction of 25% is one of the most meaningful in this space. So given all of that dynamic.
Just help us understand what gives you confidence in this.
And the guide overall.
For 2003 and for FY 'twenty for it there was a $350 million guide before with 49% gross margin can you just update us on that FY 'twenty four guide too. Thank you.
Alright, I can start and ml can Polish off what I say so in terms of when.
It gives us confidence.
We highlighted our partners.
We're strong in this last quarter.
We continue to on the NGL side, continuing to build that portfolio continuing to build that customer base.
<unk> bioscience.
Factoring in future commercialization in this last quarter has gone extremely well and as Alan highlighted on the call.
Turnaround plans are.
Excellent.
Number of customers continues to increase so in terms of the guidance outlook.
And yes and bio.
We're looking at the reduction just purely due to digesting the.
A reduction in headcount as you said is very meaningful.
Meaningful because we've invested significantly actually future thats going well.
And we're seeing opportunities in terms of upside on the same time, because we have such a meaningful reduction in head count was going to be prudent in terms of <unk>.
In terms of the Biopharma business.
Purely internal execution issues.
Absorption of Paris.
And execution.
Execution challenge in being able to integrate commercial organization could not do that for the last year, we're launching we're launching the integrated offering.
Good in terms of.
And number of active projects.
95 last quarter, we're seeing strong interests from our customer our customer base.
At the same time.
Because of the meaningful reductions we wanted to be prudent in terms of our outlook in terms of where we're going next year. As we continue as you can see the margin increase from Q3 to Q4, as we continue to leverage and factory future.
We see the benefits of the cost reductions, we will see the launch the fast genes.
Outlook for next year is to get to adjusted EBITDA breakeven by Q4.
We will continue to give updates in terms of our progress on each of the quarterly earnings call. So I'll, maybe turn it over to Emily.
To run that buyback.
I think Jim your covenant as well.
Yes.
Okay and then.
Pricing of the products can you just update US do you expect to raise any pricing on the Ngls are sym bio products and.
Overall competition in the market just can you sort of give us a sense of what youre seeing.
From some of the larger competitors the competitive dynamics changing in the market. Thank you.
Yeah, Great question. So we did our second annual.
Price increase on Ngls.
Well received.
In <unk>, we did do a price increase less less the sum of it.
None none planned at this point.
Except for launching the fast and.
<unk>.
Hello.
Our strategy is to increase the value of the product in addition to the amazing scale and.
And quintin.
Quality and ease of ordering.
We're going to add speed and using.
An approach of dynamic pricing, we are confident we'd be able to get.
The premium pricing.
Does the price increase that's coming some bio, but it's in actions to providing better value to the customer.
Thank you and our next question coming from the line of Tom Peterson with Baird. Your line is now open.
Okay.
Wondering if you could provide any more color.
The.
Our revenue expectations by product line for fiscal <unk> and <unk> given the overall reduction in the guide for the year.
Jim can you take that.
Yes, sorry.
On mute.
Yes.
So Tom Thanks for the question so overall.
We've given the guide for Boston by oil and gas.
Also for Biopharma for the year.
Just the.
The quarter quite a transition we've gone overall.
Four.
For Q3 revenues can be 60 to 61.
Q4, $62 million to $63 million is the range on a person by on the range for the year, it's 96% to 90 <unk> and.
<unk> revenue was 113 to $1 14 in Biopharma with six.
So in terms of the.
Outlook.
We believe it is prudent.
Prudent we've just taken a 25% reduction in the organization.
And yes, so I mean overall our business is up 25.
Rent year over year for total business.
The pipeline looks good.
We continue to launch new products.
We continue to get great feedback from feedback from the marketplace.
The same time.
Made a meaningful reduction in our head count really appreciate the contribution of.
Everybody, who has supported a twist in that growth.
Same time as we go forward, we're very focused on getting to profitability in the first milestone there is getting to adjusted EBITDA Q4 next year and we're positioned to do that.
And.
The overall environment.
Comments overall environment tough however, we've got a great portfolio and we're growing fast in the market.
We're going to leverage our investments.
To deliver solid results as we continue to scale and get to adjusted EBITDA breakeven.
Got it. Thanks, that's helpful. And then maybe just one more for me.
The Opex guidance reduction I mean, obviously I appreciate the significance of the head count reduction basically look forward towards that.
Adjusted EBITDA target for fiscal <unk> of next year, how should we think about if there's any more room for additional opex reductions I guess, how much flexibility do you still see left within the business.
So in terms of the business.
I mean, where nobody can predict the future.
However, what we're going to do is minus the business.
Based on the environment.
So couple of hundred key metrics.
We're growing significant in that environment.
Investments in the factory of the future, we will manage our investments and we'll manage our investments get to adjusted EBITDA breakeven and then focus on getting to profitability.
Families highlights it moderates as our investment in DNA storage. So based on the environment, we are going to make.
Take the decisions.
To ensure that we're delivering value for our shareholders our customers our employees.
And.
Part of that is having a strong balance sheet.
Another part of it is we've got to continuing strong execution and innovation that this.
Culture is known for.
Focus on supporting that and transitioning.
To the.
So the growth opportunities.
<unk> fast genes in Q4 Q4 calendar this year.
Yeah.
Okay.
Got it thanks.
Thank you and our next question coming from the line of Rachel <unk> with Jpmorgan. Your line is open.
Great. Thanks for taking the question. So a few questions from Biopharma it looks like active partnerships between legacy Biopharma in Edinburgh.
Roughly 112 active programs during fiscal <unk>.
95 during fiscal <unk> and then it looks like today you have 93 active programs. So can you just walk us through how much of that step down was really due to programs being hot and do you expect additional declines in program throughout the year and then as a follow up to that you had mentioned that challenges from Biopharma are purely just integration and occasional related.
Can you just help us understand what exactly what's the breakdown there from the integration target.
Yeah, Great question, so in terms of notes.
Another effective program noise.
We get.
We get another full a program.
We reported it as another and then probably the next quarter or the one after.
That's done.
<unk> and then that gets booked revenue and then that program goes down right and so it's not that those programs with kit.
They may have been based small number of cancellation, but most likely those are programs that but.
They have been completed and move to revenue and that's why revenue is the lagging metric and older is the leading metric and then in terms of.
The commercial integration.
We had to lead.
At various run on its own and so their territories.
Conflict.
And.
There were some technology technology has to be learned.
And.
That too.
Multi than we wanted and it happened a bit later than they will do it but at this point.
Or has it been rationalized we have re platform the systems.
And.
<unk>.
I am confident that the BD team is.
Having high activities we have.
The right cadence.
We are getting in front of new customers and closing them.
Thank you great and then.
Maybe just a follow up quick here and Theres been quite a few questions on guidance macro backdrop. So maybe I'll just shift gears over to DNA data storage.
Appreciate it that you are rationalizing some of the sponge that operating just given the macro backdrops, but can you just talk about what are your plans for your asthmatic operate if I recall you were planning on getting that fully online to support that DNA data storage operating which is going to be kind of key to the thesis in terms of the competitive positioning. It appears have entered with their own asthmatic products. So can you walk us through.
Is that timeline has shifted.
Offering and can you give us the update in terms of how that's trended as well. Thank you.
And that's a great question and so yes.
Yes, we are delaying the on premise.
Yes.
Technology development.
And we mostly.
100% needed an extended useful data on premise.
Said too that we could use <unk>.
In in house.
And.
And that will have the choice of chemical.
All in domestic.
In the current.
But she the decisive actions that we've made we have not touched the <unk> program with.
We think even even though the first product for the storage.
Is going to be an in house machine right now we saw that the days some potential advantage for us to use.
And the <unk> program that we have.
Interesting.
And so we have optionality.
Fifth stroke will be enzymatic chemicals, we're pushing both but.
Im optimistic that.
We may leverage the anthem I think <expletive> mucci for that first that the storage launch.
Thank you and I will now turn the call back over to Emily Hill depressed for any closing remarks.
Thank you very much for joining us today.
Appreciate it.
Getting a little bit.
The on schedule and we look forward to seeing some of you at Goldman Sachs, William Blair and Kushayb banks in the next few months ahead. Thank you.
Ladies and gentlemen that does conclude our conference for today. Thank you for your participation you may now disconnect.
Okay.
[music].
Okay.
[music].